Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 35, Issue 1, 2010, Pages 25-29

  Huang, Vanthida ^a,b,c   Cheung, Chrissy M ^a   Kaatz, Glenn W ^a,d,e   Rybak, Michael J ^a,b,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT RECEIVING HOSPITAL   (United States)

^c MERCER UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Community associated meticillin resistant Staphylococcus aureus; Glycopeptides; Multidrug resistant hospital associated meticillin resistant S. aureus

Indexed keywords

DALBAVANCIN; MINOCYCLINE; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; CONTROLLED STUDY; HOSPITAL INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCAL INFECTIONS;

EID: 70849136807     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.020     Document Type: Article

References (25)

1. Lowy D.F. Staphylococcus aureus infections. N Engl J Med 259 (1998) 227-230
2. Herold B.C., Immergluck L.C., Maranan M.C., Lauderdale D.S., Gaskin R.E., Boyle-Vavra S., et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279 (1998) 593-598
3. Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-10.
4. Centers for Disease Control and Prevention (CDC). Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003;52:793-5.
5. Zinderman C.E., Conner B., Malakooti M.A., LaMar J.E., Armstrong A., and Bohnker B.K. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis 10 (2004) 941-944
6. Tong S.Y.C., McDonald M.I., Holt D.C., and Currie B.J. Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in indigenous populations. Clin Infect Dis 46 (2008) 1871-1878
7. Haque N.Z., Davis S.L., Manierski C.L., Vager D., Donabedian S.M., Perri M.B., et al. Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 30 (2008) 72-77
8. Davis S.L., Rybak M.J., Amjad M., Kaatz G.W., and McKinnon P.S. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 27 (2006) 1025-1031
9. Popovich K.J., Weinstein R.A., and Hota B. Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?. Clin Infect Dis 46 (2008) 787-794
10. Oliveira D.C., and de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 2155-2161
11. Lina G., Piémont Y., Godail-Gamot F., Bes M., Peter M.O., Gauduchon V., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29 (1999) 1128-1132
12. Tristan A., Bes M., Meugnier H., Lina G., Bozdogan B., Courvalin P., et al. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 13 (2007) 594-600
13. Tenover F.C., McDougal L.K., Goering R.V., Killgore G., Projan S.J., Patel J.B., et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 44 (2006) 108-118
14. Moellering Jr. R.C. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46 (2008) 1032-1037
15. Pope S.D., and Roecker A.M. Dalbavancin: a novel lipopeptide antibacterial. Pharmacotherapy 26 (2006) 908-918
16. US Centers for Disease Control and Prevention (CDC). Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html [accessed 28 July 2007].
17. Rennie R.P., Koeth L., Jones R.N., Fritsche T.R., Knapp C.C., Killian S.B., et al. Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent. J Clin Microbiol 45 (2007) 3151-3154
18. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
19. Zhang K., McClure J., Elsayer S., Louie T., and Conly J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5026-5033
20. Goering R.V., and Winters M.A. A rapid method for the evaluation of chromosomal DNA from Gram-positive cocci by field-inversion gel electrophoresis. J Clin Microbiol 30 (1992) 577-580
21. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulse-field electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995) 2233-2239
22. Goldstein B.P., Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51 (2007) 1150-1154
23. Lopez S., Hackbarth C., Romano G., Trias J., Jabes D., and Goldstein B.P. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 55 Suppl. 2 (2005) ii21-ii24
24. Liu P., and Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am 17 (2003) 599-613
25. Tsuji B.T., Leonard S.N., Rhomberg P.R., Jones R.N., and Rybak M.J. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. Diagn Microbiol Infect Dis 60 (2008) 441-444